Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A study of thyroid function in cancer cachexia.

G Tancini1, S Barni, S Crispino

  • 1Division of Radiation Oncology, Ospedale San Gerardo, Monza, Milano, Italy.

Tumori
|April 30, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A clinical-study of immunotherapy versus endocrine therapy versus chemotherapy in the treatment of advanced pancreatic adenocarcinoma.

Oncology reports·2011
Same author

A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients.

Oncology reports·2011
Same author

Efficacy and tolerability of cancer neuroimmunotherapy with subcutaneous low-dose interleukin-2 and the pineal hormone melatonin - a progress report of 200 patients with advanced solid neoplasms.

Oncology reports·2011
Same author

Immunotherapy with subcutaneous low dose interleukin-2 plus melatonin as salvage therapy of heavily chemotherapy-pretreated ovarian cancer.

Oncology reports·2011
Same author

Immunotherapy with low-dose interleukin-2 in association with melatonin as salvage therapy for metastatic soft tissue sarcomas.

Oncology reports·2011
Same author

Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia.

Journal of biological regulators and homeostatic agents·2005
Same journal

End-of-life decisions and opinions: Results of E.L.D.Y.-CA.RE study carried out at Veneto Institute of Oncology, Italy.

Tumori·2026
Same journal

Quality indicators in identification and care of patients with genetic predisposition to cancer: An AIFET proposal.

Tumori·2026
Same journal

Driver vs. passenger: Primary resistance to larotrectinib in synovial sarcoma harboring concurrent SS18 rearrangement and PDE3A-NTRK2 fusion.

Tumori·2026
Same journal

Beyond the calendar: A narrative review on chronobiological drivers of prognosis in resectable NSCLC.

Tumori·2026
Same journal

Challenging the cornerstone: Toward risk-adapted follow-up in early breast cancer.

Tumori·2026
Same journal

Assessing in house comprehensive genomic profiling by liquid biopsy for NSCLC patients.

Tumori·2026
See all related articles

Cancer cachexia mechanisms remain unclear. This study found that cachectic cancer patients had higher levels of the active thyroid hormone T3, suggesting its altered production may contribute to cancer cachexia.

Area of Science:

  • Endocrinology
  • Oncology
  • Metabolic Disorders

Background:

  • Cancer cachexia is a complex metabolic syndrome characterized by involuntary weight loss.
  • The exact mechanisms driving cancer cachexia are not fully understood.
  • The hypothalamic-pituitary-thyroid axis is a potential regulator of metabolic processes implicated in cachexia.

Purpose of the Study:

  • To investigate the role of the hypothalamic-pituitary-thyroid axis in cancer cachexia.
  • To compare thyroid hormone levels in cachectic cancer patients, non-cachectic cancer patients, and control groups.

Main Methods:

  • Serum levels of thyroid hormones (T3, FT3, T4, FT4), TSH, and TBG were measured.
  • Patients included 26 advanced cancer patients (14 cachectic, 12 non-cachectic), 58 healthy controls, and 11 patients with benign weight loss.

Related Experiment Videos

Main Results:

  • Low T3 and FT3 levels were observed in benign weight loss patients and non-cachectic cancer patients.
  • Cachectic cancer patients showed significantly higher mean serum T3 and FT3 levels compared to non-cachectic cancer patients and benign weight loss patients.
  • Only a minority (4/14) of cachectic cancer patients exhibited decreased T3 and FT3 values.

Conclusions:

  • The active thyroid hormone T3 levels are not decreased in most cachectic cancer patients.
  • Elevated T3 and FT3 levels in cachectic cancer patients may indicate a role in the pathogenesis of cancer cachexia.
  • Further research is needed to elucidate the precise mechanisms involving the thyroid axis in cancer cachexia.